Nguta Joseph Mwanzia, Appiah-Opong Regina, Nyarko Alexander K, Yeboah-Manu Dorothy, Addo Phyllis G A
Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana; Department of Public Health, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, Kenya.
Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.
Int J Mycobacteriol. 2015 Sep;4(3):165-83. doi: 10.1016/j.ijmyco.2015.05.004. Epub 2015 Jun 3.
Currently, one third of the world's population is latently infected with Mycobacterium tuberculosis (MTB), while 8.9-9.9 million new and relapse cases of tuberculosis (TB) are reported yearly. The renewed research interests in natural products in the hope of discovering new and novel antitubercular leads have been driven partly by the increased incidence of multidrug-resistant strains of MTB and the adverse effects associated with the first- and second-line antitubercular drugs. Natural products have been, and will continue to be a rich source of new drugs against many diseases. The depth and breadth of therapeutic agents that have their origins in the secondary metabolites produced by living organisms cannot be compared with any other source of therapeutic agents. Discovery of new chemical molecules against active and latent TB from natural products requires an interdisciplinary approach, which is a major challenge facing scientists in this field. In order to overcome this challenge, cutting edge techniques in mycobacteriology and innovative natural product chemistry tools need to be developed and used in tandem. The present review provides a cross-linkage to the most recent literature in both fields and their potential to impact the early phase of drug discovery against TB if seamlessly combined.
目前，全球三分之一的人口潜伏感染结核分枝杆菌（MTB），而每年报告的结核病（TB）新发病例和复发病例有890万至990万。对天然产物重新燃起研究兴趣，以期发现新的抗结核先导物，部分原因是MTB多重耐药菌株的发病率上升，以及一线和二线抗结核药物的不良反应。天然产物一直是、也将继续是许多疾病新药的丰富来源。源自生物体产生的次生代谢产物的治疗药物的深度和广度，是其他任何治疗药物来源都无法比拟的。从天然产物中发现针对活动性和潜伏性结核病的新化学分子需要跨学科方法，这是该领域科学家面临的一项重大挑战。为了克服这一挑战，需要同时开发和使用分枝杆菌学的前沿技术和创新的天然产物化学工具。本综述提供了这两个领域最新文献的交叉联系，以及如果无缝结合，它们对结核病药物发现早期阶段产生影响的潜力。
